BioAtla
Update in progressBCAB (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
BioAtla, Inc. is a clinical-stage biopharmaceutical company developing conditionally active biologic (CAB) antibody-based therapeutics for solid tumors. Lead programs include mecbotamab vedotin (BA3011) for undifferentiated pleomorphic sarcoma and NSCLC; ozuriftabmab vedotin (BA3021) for melanoma and head and neck squamous cell carcinoma; Evalstotug (BA3071), an anti-CTLA-4 CAB, for melanoma, RCC, colorectal cancer and NSCLC. The pipeline also includes BA3182 (bispecific), BA3361 (CAB-Nectin-4-ADC), and BA3142 (dual-CAB T-cell engager targeting B7-H3). Founded 2007, based in San Diego, CA.
Company score
- Sentiment
- -0.25
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.45
- Governance
- -0.05
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.14
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Jay M. Short Ph.D.
- Founded2007
- Employees41
- Websitewww.bioatla.com
Identifiers
- ISINUS09077B1044
- FIGIBBG00Y6GBT61
- CUSIP09077B104
- CIK0001826892